Research programme: virus-like particle vaccines - VBI Vaccines

Drug Profile

Research programme: virus-like particle vaccines - VBI Vaccines

Alternative Names: CMV eVLP - VBI; eVLP vaccines - VBI; GBM eVLP - VBI; Glioblastoma eVLP Vaccine - VBI Vaccines; Glioblastoma Immunotherapy; HCV eVLP - VBI; Prophylactic respiratory syncytial virus vaccine - VBI Vaccines; RSV vaccine - VBI Vaccines; VBI 1901; VBI-2501; VLP-based Cytomegalovirus - VBI; Zika virus eVLP vaccine - VBI Vaccines; Zika virus vaccine - VBI Vaccines

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VBI Vaccines
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action Cytomegalovirus protease inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Glioblastoma; Hepatitis C; Medulloblastoma; Zika virus infection
  • Research Respiratory syncytial virus infections

Most Recent Events

  • 16 Aug 2017 FDA accepts an IND application for VBI 1901 for Glioblastoma (Recurrent) in USA
  • 15 Aug 2017 VBI Vaccines plans a phase I/IIa trial for Glioblastoma (Recurrent) in USA in the second half of 2017
  • 11 Oct 2016 VBI Vaccines announces intention to submit IND to US FDA in 1H-2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top